We need to change direction on therapies for unresectable or metastatic nonmelanoma skin cancers, pronounced Thomas Olencki, DO, Clinical Professor of Internal Medicine and Vice Chair of the Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, and a member of NCCN panels on genitourinary and nonmelanoma skin cancers. The approaches of the past were based on limited objective data, with no statistical significance from studies with small numbers of patients.
During his presentation at the NCCN 19th Annual Conference, Dr. Olencki reviewed some of the less-than-optimal treatments of the past and some of the more promising contemporary therapies for patients with cutaneous squamous cell carcinoma (SCC), metastatic basal cell carcinoma (BCC), and metastatic Merkel cell carcinoma (MCC). Dr. Olencki noted the few options available for these rare cancers and a lack of clinical trials for guidance, and shared his thoughts and experience with newer treatment regimens, including some of the clinical data behind them.
Lippman SM, Parkinson DR, Itri LM. 13-Cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 1992;84:235–241.
Brewster AM, Lee JJ, Clayman GL. Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. J Clin Oncol 2007;25:1974–1978.
Guthrie TH Jr, Porubsky ES, Luxenberg MN. Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol 1990;8:342–348.
Solomon SD, McMurray JJ, Pfeffer MA. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071–1080.
Elmets CA, Viner JL, Pentland AP. Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 2010;102:1835–1844.
Bauman JE, Eaton KD, Martins RG. Treatment of recurrent squamous cell carcinoma of the skin with cetuximab. Arch Dermatol 2007;143:888–892.
Maubec E, Petrow P, Scheer-Senyarich I. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 2011;29:3419–3426.
Mecca C, Ponzetti A, Caliendo V. Complete response of metastatic cutaneous squamous cell carcinoma to cetuximab plus paclitaxel. Eur J Dermatol 2012;22:758–761.
Sekulic A, Migden MR, Oro AE. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012;366:2171–2179.
Axelson M, Liu K, Jiang X. U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma. Clin Cancer Res 2013;19:2289–2293.
Lorusso PM, Jimeno A, Dy G. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0499) in patients with locally advanced or metastatic solid tumors. Clin Cancer Res 2011;17:5774–5782.
Samlowski WE, Moon J, Tuthill RJ. A phase II trial of imatinib mesylate in Merkel cell carcinoma (neuroendocrine carcinoma of the skin): a Southwest Oncology Group study (S0331). Am J Clin Oncol 2010;33:495–499.